Source: https://patents.google.com/patent/US8652534B2/en
Timestamp: 2019-05-21 07:54:43
Document Index: 659857303

Matched Legal Cases: ['art-24', 'art-24', 'art-24', 'art-24', 'art-24', 'art-24', 'art 1']

US8652534B2 - Compositions and methods for treatment of mammalian skin - Google Patents
Compositions and methods for treatment of mammalian skin Download PDF
US8652534B2
US8652534B2 US12/661,567 US66156710A US8652534B2 US 8652534 B2 US8652534 B2 US 8652534B2 US 66156710 A US66156710 A US 66156710A US 8652534 B2 US8652534 B2 US 8652534B2
US12/661,567
US20110086088A1 (en
Berry Pharmaceuticals LLC
2009-10-14 Priority to US27264109P priority Critical
2010-03-19 Application filed by Berry Pharmaceuticals LLC filed Critical Berry Pharmaceuticals LLC
2010-03-19 Priority to US12/661,567 priority patent/US8652534B2/en
2010-03-19 Assigned to BERRY PHARMACEUTICALS, L.L.C. reassignment BERRY PHARMACEUTICALS, L.L.C. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERRY, DON WAYNE
2011-04-14 Publication of US20110086088A1 publication Critical patent/US20110086088A1/en
2014-02-18 Publication of US8652534B2 publication Critical patent/US8652534B2/en
Compositions of matter useful for treating a disorder present on mammalian skin selected from the group consisting of: pre-cancerous lesions, keratotic lesions, superficial basal cell carcinomae; squamous cell carcinomae; malignant melanoma, radiation-induced burns and other conditions, which compositions comprise a pharmaceutically-acceptable carrier in combination with at least one material selected from the group consisting of: an alkaloid, pigenin-7-o-beta d-glucuronide; aricine; catequine; 24-methylenecycloartane-3β-ol; 24-methylcycloart-24-en-3β-ol; 2 E-3,7,11,15,19-pentamethyl-2-eicosane-1-ol; ephedrine; flavonones; 2′-5-5′-7-tetrahydroxy-7-o-rutinoside; isomaruquine; isopteropodine; maruquine; the methyl ester of maruquine; narirutin; narirutin (2r); narirutin (2s); oxindole alkaloids; oxindole aricine; palmirine; pteropodine; rumberine; rosmarinic acid; rotundic acid; rumberine; rutin; seneciophylline; β-sitosterol; speciophylline; stigmast-4-en-3-3-dione; stigmast-4-en-3-6-dione; stigmasterol; tannins; and ursolic acid, and including any mixtures thereof, present in an effective amount for alleviating symptoms of said disorder.
A hamelia patens extract provided according to some embodiments of the disclosure contains at least any one compound, and in other embodiments contains any mixture comprising a plurality including any two or more than two compounds present in the listing now set forth, the compounds in such listing comprising: alkaloids; 2-alpha-hydroxyursolic acid, apigenin-7-o-beta d-glucuronide, aricine, catequine, 19-alphahydroxy Asiatic acid, 24-methylenecycloartane-3β-ol, 24-methylcycloart-24-en-3β-ol, 2 E-3,7,11,15,19-pentamethyl-2-eicosane-1-ol, ephedrine, flavonones, 2′-5-5′-7-tetrahydroxy-7-o-rutinoside, isomaruquine, isopteropodine, maruquine, the methyl ester of maruquine, mitraphylline, narirutin, narirutin (2r), narirutin (2s), oxindole alkaloids, oxindole aricine, palmirine, pigenin-7-o-beta D-glucuronide, pomolic acid, pteropodine, rumberine, rosmarinic acid, rotundic acid, rumberine, rutin, seneciophylline, β-sit osterol, speciophylline, stigmast-4-en-3-3-dione, stigmast-4-en-3-6-dione, stigmasterol, tannins, tormentic acid, uncarine F, and ursolic acid. In some embodiments, all of these compounds are present in a hamelia patens extract useful for providing a composition according to this disclosure.
In some embodiments catequine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains 24-methylenecycloartane-3,3-ol. In some embodiments 24-methylenecycloartane-3β-ol is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains 24-methylcycloart-24-en-3β-ol. In some embodiments 24-methylcycloart-24-en-3β-ol is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains 2 E-3,7,11,15,19-pentamethyl-2-eicosane-1-ol. In some embodiments 2 E-3,7,11,15,19-pentamethyl-2-eicosane-1-ol is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains ephedrine. In some embodiments ephedrine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains flavonones. In some embodiments flavonones are present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains 2′-5-5′-7-tetrahydroxy-7-o-rutinoside. In some embodiments 2′-5-5′-7-tetrahydroxy-7-o-rutinoside is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains 19-alpha-hydroxy asiatic acid. In some embodiments 19-alpha-hydroxy asiatic acid is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains isomaruquine. In some embodiments isomaruquine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains isopteropodine. In some embodiments isopteropodine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains maruquine. In some embodiments maruquine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains the methyl ester of maruquine. In some embodiments the methyl ester of maruquine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains mitraphylline. In some embodiments mitraphylline is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains narirutin. In some embodiments narirutin is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains narirutin (2r). In some embodiments narirutin (2r) is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains narirutin (2s). In some embodiments narirutin (2s) is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains oxindole alkaloids. In some embodiments oxindole alkaloids are present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains oxindole In some embodiments oxindole aricine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains palmirine. In some embodiments palmirine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains pigenin-7-o-beta D-glucuronide. In some embodiments pigenin-7-o-beta D-glucuronide is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains pomolic acid. In some embodiments pomolic acid is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains pteropodine. In some embodiments pteropodine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains rumberine. In some embodiments rumberine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains rosmarinic acid. In some embodiments rosmarinic acid is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains rotundic acid. In some embodiments rotundic acid is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains rumberine. In some embodiments rumberine is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains rutin. In some embodiments rutin is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains seneciophylline. In some embodiments seneciophylline is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains β-sit osterol. In some embodiments β-sitosterol is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains speciophylline. In some embodiments speciophylline is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains stigmast-4-en-3-3-dione. In some embodiments stigmast-4-en-3-3-dione is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains stigmast-4-en-3-6-dione. In some embodiments stigmast-4-en-3-6-dione is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains stigmasterol. In some embodiments stigmasterol is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains tannins. In some embodiments tannins are present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains tormentic acid. In some embodiments tormentic acid is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains uncarine F. In some embodiments uncarine F is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains ursolic acid. In some embodiments ursolic acid is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. A hamelia patens extract as provided in some embodiments contains 2-alpha-hydroxy ursolic acid. In some embodiments 2-alpha-hydroxy ursolic acid is present in a composition according to the disclosure in any amount between about 0.05% and about 30% by weight based on the total weight of the composition, including all weight percents and ranges of weight percents therebetween. Terms including “about” when used herein, such as “about 30%”, are understood as also including the exact numerical value occurring immediately subsequent to “about”, in the same context, i.e., such a recitation as “about 30%” includes the exact value specified, in this instance exactly 30%. In some embodiments, each of the component materials in the listing above, when present in a hamelia patens extract, are present in amounts within their specified ranges independently with respect to the amounts of the other components present.
This disclosure includes hamelia patens extracts from which some of the components in the listing above have been removed, and also hamelia patens extracts comprising a plurality of the materials in the listing above which are produced by combining previously-isolated purified component materials from such listing. In some embodiments, all alkaloids are omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all 2-alpha-hydroxyursolic acid is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all flavonones are omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all apigenin-7-o-beta d-glucuronide is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all aricine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all catequine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all flavonones is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all 19-alphahydroxy Asiatic acid is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all 24-methylenecycloartane-3β-ol is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all 24-methylcycloart-24-en-3β-ol is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all 2 E-3,7,11,15,19-pentamethyl-2-eicosane-1-ol is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all ephedrine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all 2′-5-5′-7-tetrahydroxy-7-o-rutinoside is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all flavonones are omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all isomaruquine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all isopteropodine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all maruquine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all the methyl ester of maruquine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all mitraphylline is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all narirutin is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all narirutin (2r) is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all narirutin (2s) is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all oxindole alkaloids are omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all oxindole aricine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all palmirine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all pigenin-7-o-beta D-glucuronide is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all pomolic acid is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all pteropodine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all rumberine is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all rosmarinic acid is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all rotundic acid is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all rutin is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all seneciophylline is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all β-sit osterol is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all speciophylline is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all stigmast-4-en-3-3-dione is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all stigmast-4-en-3-6-dione is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all stigmasterol is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all tannins are omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all tormentic acid is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all uncarine F is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. In some embodiments, all ursolic acid is omitted or removed when providing a hamelia patens extract according to the disclosure, the remaining components of the listing remaining present. As a non-limiting example, in some embodiments, all flavones, all rutin, and ephedrine are removed or omitted, the remaining components of the listing remaining present in a hamelia patens extract according to this disclosure; however, any one or combination including more than one material in the listing may be removed or omitted. A combination, including a hamelia patens extract, according to the disclosure and useful in accordance with providing compositions according to some embodiments of this disclosure may thus contain any number between about one and about all of the foregoing materials in the listing, in any combination, each, when present, being independently present in any amount within the ranges specified above.
EXAMPLE I Petrolatum Extract of Hamelia Patens
EXAMPLE II Aqueous Alcohol Extract of Hamelia Patens
EXAMPLE III Crystalline Extract of Hamelia Patens
EXAMPLE IV Lotion
EXAMPLE V Vitamin-Fortified Lotion
EXAMPLE VI Lotion Concentrate
EXAMPLE VII Laundry Detergent
EXAMPLE VIII Laundry Detergent
EXAMPLE IX Salve Containing Hamelia Patens
EXAMPLE X Hand Soap
EXAMPLE XI Injectable Solution
EXAMPLE XII Dental Paste
EXAMPLE XIII Oil in Water Emulsion
EXAMPLE XIV Treatment for Solar Keratosis
EXAMPLE XV Treatment for Solar Keratosis
1. A method for treating pre-cancerous lesions present in or on a mammalian subject which method comprises contacting a composition containing a hamelia patens extract to the skin of said subject in an effective amount and frequency for reducing symptoms of pre-cancerous lesions.
2. The method according to claim 1 wherein said extract comprises an effective symptom-reducing amount of at least one material selected from the group consisting of: alkaloids, 2-alpha-hydroxyursolic acid, apigenin-7-o-beta d-glucuronide, aricine, catequine, 19-alphahydroxy Asiatic acid, 24-methylenecycloartane-3β-ol, 24-methylcycloart-24-en-3β-ol, 2 E -3,7,11,15,19-pentamethyl-2-cicosane-1-ol, ephedrine, flavonones, 2′-5-5′-7-tetrahydroxy-7-o-rutinoside, isomaruquinc, isopteropodine, maruquine, the methyl ester of maruquine, mitraphylline, narirutin, narirutin (2r), narirutin (2s), oxindole alkaloids, oxindole aricine, palmirine, pigenin-7-o-beta D-glucuronide, pomolic acid, pteropodine, rosmarinic acid, rotundic acid, rumberine, rutin, seneciophylline, β-sitosterol, speciophylline, stigmast-4-en-3-3-dione, stigmast-4-en-3-6-dione, stigmasterol, tannins, tormentic acid, uncarine F, and ursolic acid, and including any mixtures thereof.
3. The method according to claim 2 wherein said composition comprises all of said materials recited in said group.
4. The method according to claim 2 wherein each material selected to be present in said composition is independently present in any amount between 0.05% by weight and 30% by weight based on the total weight of said composition, including all weight percentages and ranges of weight percentages therebetween.
5. The method according to claim 2, wherein said composition is in any form selected from the group consisting of: salves, creams, ointments, and lotions.
6. The method according to claim 1 wherein said composition comprises any carrier selected from the group consisting of: water, saline solution, any C1 to C4 alcohol, any glyceryl ester oil, and any mineral oil.
7. The method according to claim 1 wherein said composition comprises a nanoparticle.
8. The method according to claim 7 wherein said nanoparticle is selected from the group consisting of: solid core nanoparticles, hollow core nanoparticles, lipid nanoparticles, PEG nanoparticles, and chitosan nanoparticles, including mixtures thereof.
9. The method according to claim 1 wherein said composition comprises a liposome.
10. The method according to claim 1 wherein said extract is an aqueous extract.
11. The method according to claim 1 wherein said extract is a non-aqueous extract.
12. A The method according to claim 1 wherein said composition comprises a pharmaceutically-acceptable carrier.
US12/661,567 2009-10-14 2010-03-19 Compositions and methods for treatment of mammalian skin Active 2031-01-20 US8652534B2 (en)
US27264109P true 2009-10-14 2009-10-14
US12/661,567 US8652534B2 (en) 2009-10-14 2010-03-19 Compositions and methods for treatment of mammalian skin
PCT/US2011/000496 WO2011126539A2 (en) 2010-03-19 2011-03-18 Compositions and methods for treatment of mammalian skin
US13/815,957 US9345736B2 (en) 2009-10-14 2013-03-16 Topical treatment of radiation dermatitis using hamelia patens
US13/999,350 US9345737B2 (en) 2009-10-14 2014-02-12 Topical treatment of keratotic lesions using hamelia patens
US13/999,341 US20140193478A1 (en) 2009-10-14 2014-02-12 Compositions and methods for treatment on mammalian skin
US13/815,957 Continuation US9345736B2 (en) 2009-10-14 2013-03-16 Topical treatment of radiation dermatitis using hamelia patens
US13/815,957 Continuation-In-Part US9345736B2 (en) 2009-10-14 2013-03-16 Topical treatment of radiation dermatitis using hamelia patens
US13/999,350 Division US9345737B2 (en) 2009-10-14 2014-02-12 Topical treatment of keratotic lesions using hamelia patens
US13/999,350 Continuation US9345737B2 (en) 2009-10-14 2014-02-12 Topical treatment of keratotic lesions using hamelia patens
US13/999,341 Division US20140193478A1 (en) 2009-10-14 2014-02-12 Compositions and methods for treatment on mammalian skin
US20110086088A1 US20110086088A1 (en) 2011-04-14
US8652534B2 true US8652534B2 (en) 2014-02-18
ID=43855042
US12/661,567 Active 2031-01-20 US8652534B2 (en) 2009-10-14 2010-03-19 Compositions and methods for treatment of mammalian skin
US13/815,957 Active US9345736B2 (en) 2009-10-14 2013-03-16 Topical treatment of radiation dermatitis using hamelia patens
US13/999,350 Active US9345737B2 (en) 2009-10-14 2014-02-12 Topical treatment of keratotic lesions using hamelia patens
US13/999,341 Abandoned US20140193478A1 (en) 2009-10-14 2014-02-12 Compositions and methods for treatment on mammalian skin
US (4) US8652534B2 (en)
WO (1) WO2011126539A2 (en)
TWI413646B (en) * 2010-09-03 2013-11-01 Univ China Medical Pharmaceutical composition for inhibiting activity and/or expression of matrix metalloproteinase, inhibiting phosphorylation of mitogen-activated protein kinase, and/or promoting expression of collagen and uses of the same
CA2942070A1 (en) * 2014-03-14 2015-09-17 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
WO2015167548A1 (en) * 2014-04-30 2015-11-05 Kimberly-Clark Worldwide, Inc. Topical compositions including an undaria extract for reducing signs of skin aging
US20180185409A1 (en) 2015-07-10 2018-07-05 Infectopharm Arzneimittel Und Consilium Gmbh Use of potassium hydroxide in the treatment of actinic keratosis
CN106883282B (en) * 2017-02-22 2019-01-29 吉林省中医药科学院（吉林省中医药科学院第一临床医院） Rotundic acid derivative is preparing the application in anti-tumor drug
WO1994015902A1 (en) 1993-01-11 1994-07-21 Ligand Pharmaceuticals Inc. Compounds having selectivity for retinoid x receptors
EP0933351A1 (en) 1994-12-30 1999-08-04 Ligand Pharmaceuticals Incorporated Tricyclic retinoids, methods for their production and use
JP2002020232A (en) 2000-07-06 2002-01-23 Kose Corp Skin care preparation and skin care composition
US20030103953A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard Allen Composition and method for prevention, reduction and treatment of radiation dermatitis
WO2005058255A1 (en) 2003-12-18 2005-06-30 Nestec S.A. Composition for improving skin, hair and coat health containing flavanones
US20070219141A1 (en) * 2003-12-08 2007-09-20 David Jones Plant Materials Extraction Method
US7273625B2 (en) 2000-04-21 2007-09-25 Lee Insu P Minari extract for preventing the induction and metastasis of cancer by carcinogens contained in cigarette smoke, fermented foods or alcoholic drinks
WO2008109717A1 (en) 2007-03-05 2008-09-12 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
2010-03-19 US US12/661,567 patent/US8652534B2/en active Active
2011-03-18 WO PCT/US2011/000496 patent/WO2011126539A2/en active Application Filing
2013-03-16 US US13/815,957 patent/US9345736B2/en active Active
2014-02-12 US US13/999,350 patent/US9345737B2/en active Active
2014-02-12 US US13/999,341 patent/US20140193478A1/en not_active Abandoned
Biosci. Biotechnol. Biochem, 68(1) pp. 85-90 (2004) Banno et al.
British Journal of Haemotology, 132 pp. 615-622 (2005) Bacher et al.
Cancer Letters 219 pp. 49-55 (2005) Fernandes et al.
Carcinogenesis, vol. 25, No. 4, pp. 549-557 (2004) Osakabe et al.
Chem. Pharm. Bull. 54(5) pp. 561-564 (2005) Lim et al.
Einspahr et al., "Chemoprevention of human skin cancer", 2002, Critical Reviews in Oncology/Hematology, vol. 41, pp. 269-285. *
Esposito-Avella et al. "Pharmacological Screening of Panamanian Medicinal Plants, Part 1" J. Crude Drug Res. 23 (1985) No. 1, pp. 17-25.
Gomez-Beloz et al.; Double Incision Wound Healing Bioassay Using Hamelia patens from El Salvador; 2003; Journal of Ethnopharmacology; 88; pp. 169-173. *
Journal of Ethnopharmacology, vol. 87 pp. 103-107 (2003).
List of chemical constituents of Hamelia patens, from www.rain-tree.com dated 2004 (2 pages).
Lopez Abraham et al. "Extractos de plantas con propiedades citostaticas que crecen en Cuba", Rev. Cub Med Trop 31: 2. 1979. English translation also included.
Ocampo, R. & Balick, M. "Plants of Semillas Sagradas: An Ethnobedicinal Garden in Costa Rica", 2009 Finca Luna Nueva Extractos de Costa Rica, ISBN 978-0-615-27415-7.
Page 505 from Scarlet bush, ED-Taylor L in "The Healing Power of Rainforest Herbs, Squareone"-Jan. 1, 2005 XP009152071.
Page 505 from Scarlet bush, ED—Taylor L in "The Healing Power of Rainforest Herbs, Squareone"—Jan. 1, 2005 XP009152071.
Phytomedicine 14 pp. 280-284 (2007) Prado et al.
Sosa, S. et al. "Screening of the topical anti-inflammatory activity of some Central American plants", Medicinal & Armoatic Plants Abstracts, Scientific Publishers, New Delhi, India, vol. 24, No. 6, (2002); ISSN: 0250-4367.
Taylor, Leslie; The Healing Power of Rainforest Herbs: A Guide to Understanding and Using Herbal Medicinals; 2005; Square One Publishers; pp. 144, 145, 417-420, and 505. *
Web page printout http://emedicine.medscape.com/article/216993-overview, Apr. 19, 2012.
Web page printout http://en.wikipedia.org/wiki/Enterococcus, Jun. 19, 2012.
Web page printout http://en.wikipedia.orq/wiki/Enterococcus-faecalis, Apr. 19, 2012.
Web page printout http://en.wikipedia.orq/wiki/Enterococcus—faecalis, Apr. 19, 2012.
Web page printout http://www.druglib.com/druginfo/levaguin/indications-dosage, Apr. 20, 2012.
Web page printout http://www.druglib.com/druginfo/levaguin/indications—dosage, Apr. 20, 2012.
Web page printout http://www.en.wikipedia.org/wiki/Anaerobic-infection, Apr. 19, 2012.
Web page printout http://www.en.wikipedia.org/wiki/Anaerobic—infection, Apr. 19, 2012.
Web page printout http://www.livestrong.com/article/230179-enterococcus-faecalis-symptoms, Apr. 19, 2012.
www.cosmeticsdesign.com/Formulation-Science/New-ursolic-acid-ingredient-given-global-launch (2006) 3 pages.
www.ursolicacid.com/inhibition.htm dated 2001 2 pages.
www.ursolicare.com 6 pages.
WO2011126539A2 (en) 2011-10-13
US20140193479A1 (en) 2014-07-10
US20140193478A1 (en) 2014-07-10
US20130251825A1 (en) 2013-09-26
US9345736B2 (en) 2016-05-24
US9345737B2 (en) 2016-05-24
WO2011126539A3 (en) 2012-03-15
US20110086088A1 (en) 2011-04-14
JP2005535614A (en) 2005-11-24 The topical cosmetic composition
LU83173A1 (en) 1981-06-05 New cosmetic compositions for the treatment of hair and skin containing a powder resulting from the spray at least a plant and a cohesion agent
US20030202951A1 (en) 2003-10-30 Method for reducing the appearance of dark circles under the eyes
WO2001095872A1 (en) 2001-12-20 Cosmetic and/or dermatological composition based on cocoa extracts
JP3661707B2 (en) 2005-06-22 External preparation for skin
Owner name: BERRY PHARMACEUTICALS, L.L.C., TEXAS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BERRY, DON WAYNE;REEL/FRAME:024157/0797